Strictly by the numbers:
15K patients worldwide
@ $300K/year per patient
$4.5B/year in revenues
Divided by the 28M shares outstanding
So the earnings based valuation model is is:
$1,600/share at a PE of 10
$3,150/share at a PE of 20
$6,300/share at a PE of 40
Makes a buyout irresistible.
Updated patient numbers should favor AEGR stock pop.
Patient counts continue to rise, as do revenues and profit$.
Look for AEGR to be added to biotech indexes now that market cap is increasing. It will snowball from there.
Valuations hold. $6K is still the target. Whether we get there in 2016 or 2018 or 2020 is the question.
Soon to cross over the $100/share line.
EU coming on line to contribute to the revenue stream.
End of the double digits is coming soon.
Keeps going up as new patients are added every single day.
This value is beginning to be realized as patients continue to benefit from the drug, and patient counts keep rising,
New price target at Citi is $125/share.